Merrimack Pharmaceuticals Inc. (MACK)
Россия
  • Россия
  • Украина

Merrimack Pharmaceuticals Inc. (MACK)

Contact Details

1 Kendall Sq Ste B7201, Cambridge, Massachusetts, USA 02139-1670
(617) 441-1000
1 Kendall Sq Ste B7201, Cambridge, Massachusetts, USA 02139-1670

General Information

Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Contact Information

Phone(617) 441-1000
Fax(617) 491-1386
Website 1http://www.merrimackpharma.com
Twitter@MerrimackPharma
Thomson Reuters PermID5001210278

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO and President$1,729,1592014-15.2%
CFO and Treasurer$645,1512014-33.4%
Other Corporate Officer$881,84420143.2%
Other Corporate Officer$897,5812014
Chief Scientific Officer and Senior VP$1,317,6082014-9.6%

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing
  • Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

SIC Industries

  • Pharmaceutical Preparations
  • Commercial Physical Research

Company Size

Sales Volume$89.3 million
Employees426

Ownership

Ticker SymbolMACK
ExchangeNASDAQ Global Market
Year Founded1993

Stocks

Previous Close8.49
Open8.50
Bid8.14 x 400
Ask8.15 x 100
Day`s Range8.05 - 8.50
52-Week Range5.27 - 13.67
Average Volume (1M)2,173,202
Beta1.95x
Market Cap.$1,003.93 Million
Last Dividend Amount0
1y Target Price Est.15.8

Pre-IPO

Summary of Form-D Filings

    Filing History

  • Merrimack Pharmaceuticals Inc. has filed 1 Form Ds since 2008. Of these filings, 1 has been for a unique offering.
  • Through these filings, they have raised $77,000,000.
  • They have not paid finder`s fees or sales commissions in connection with these offerings.
  • They have not used any of the proceeds from its offerings to pay officers or directors.
  • The types of securities they have issued are Equity.
  • They have relied on the following exemptions in past filings Rule 506.

    Analysis of Past Filings

  • Merrimack Pharmaceuticals Inc. has filed about as many filings as an average company in the Pharmaceuticals category.
  • They have had about as many unique offerings as an average company in the Pharmaceuticals category.
  • The total amount raised they have raised is 2,487% higher than the average for a company in the Pharmaceuticals category.

Form-D Filings

Filing DateFiling TypeTotal Offering AmountTotal Amount RaisedTotal Remaining For Sale
April 11, 2011New$77,000,000$77,000,000$0

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue21,41816,44036,55814,842
Cost of Revenue----
Gross Profit21,41816,44036,55814,842
Research Development44,74037,76342,80635,679
Selling General and Administrative19,33516,95612,3159,189
Depreciation and Amortization----
Other Operating Expenses46---
Total Operating Expenses64,12154,71955,12144,868
Other Income/Expenses Net----
Earnings Before Interest and Taxes(42,703)(38,279)(18,563)(30,026)
Interest Expense5,7084,4764,4824,566
Income Before Tax(48,068)(42,386)(22,901)(34,432)
Income Tax Expense----
Minority Interest----
Net Income from Continuing Ops(48,068)(42,386)(22,901)(34,432)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items242(208)123(327)
Net Income(47,826)(42,594)(22,778)(34,759)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(47,826)(42,594)(22,778)(34,759)